Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells

@article{Araki2013NegligibleIO,
  title={Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells},
  author={Ryoko Araki and M. Uda and Yuko Hoki and Misato Sunayama and Miki Nakamura and Shunsuke Ando and Mayumi Sugiura and Hisashi Ideno and Akemi Shimada and Akira Nifuji and Masumi Abe},
  journal={Nature},
  year={2013},
  volume={494},
  pages={100-104}
}
The advantages of using induced pluripotent stem cells (iPSCs) instead of embryonic stem (ES) cells in regenerative medicine centre around circumventing concerns about the ethics of using ES cells and the likelihood of immune rejection of ES-cell-derived tissues. However, partial reprogramming and genetic instabilities in iPSCs could elicit immune responses in transplant recipients even when iPSC-derived differentiated cells are transplanted. iPSCs are first differentiated into specific types… 

Brief Report: Immune Microenvironment Determines the Immunogenicity of Induced Pluripotent Stem Cell Derivatives

It is shown that the immune response toward antigens is dependent on the immune environment of the transplantation site, and the cotransplantation of mature B6 dendritic cells under the kidney capsule leads to immune rejection of B6 iPSC‐derived grafts but not B6 ESC‐ derived grafts.

The immunogenicity of cells derived from induced pluripotent stem cells

  • Xuemei Fu
  • Biology
    Cellular and Molecular Immunology
  • 2014
A recent breakthrough in the technology of induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient-specific somatic cells with defined factors could become a renewable source of autologous cells for cell therapy.

Low immunogenicity of mouse induced pluripotent stem cell-derived neural stem/progenitor cells

The immunogenicity and post-transplantation immunological dynamics of iPSC-NSPCs resemble those of fetus-N SPCs.

The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives

The mechanism underlying the immunogenicity of the pluripotent stem cells and recent progress in developing immune tolerance strategies of human pluripoline stem cell (hPSC)-derived allografts are discussed.

pluripotent stem cells Potentially immunogenic proteins expressed similarly in human embryonic stem cells and induced

Whether the human homologs of these markers, HORMAD1, ZG16, and Cyp3A, are differentially expressed in human iPS versus ES cells, as well as undifferentiated and in vitro-differentiated cells is examined.

Reduced Immunogenicity of Induced Pluripotent Stem Cells Derived from Sertoli Cells

The findings indicate that early-passage Ser-iPS cells retain some somatic memory of Sertoli cells that impacts on immunogenicity of iPS cells and iPS cell-derived cells in vivo and in vitro, and suggest that immune-privileged SERToli cells might represent a preferred source for iPScell generation, if it comes to the use of i PS cell- derived cells for transplantation.

Potentially immunogenic proteins expressed similarly in human embryonic stem cells and induced pluripotent stem cells

Whether the human homologs of these markers, HORMAD1, ZG16, and Cyp3A, are differentially expressed in human iPS versus ES cells, as well as undifferentiated and in vitro-differentiated cells is examined.

Immune tolerance of human induced pluripotent stem cell-derived myogenic progenitor cells in humanized mice

The results showed that while allogeneic grafts were rejected and highly infiltrated with human T cells, engraftment of autologous cells was tolerated, indicating reprogramming and differentiation procedures are not immunogenic.

Low Immunogenicity of Neural Progenitor Cells Differentiated from Induced Pluripotent Stem Cells Derived from Less Immunogenic Somatic Cells

The groundbreaking discovery of induced pluripotent stem cells (iPS cells) provides a new source for cell therapy. However, whether the iPS derived functional lineages from different cell origins
...

References

SHOWING 1-10 OF 43 REFERENCES

Immunogenicity of induced pluripotent stem cells

Findings indicate that, in contrast to derivatives of ESCs, abnormal gene expression in some cells differentiated from iPSCs can induce T-cell-dependent immune response in syngeneic recipients.

Immunogenicity of induced pluripotent stem cells.

A new study shows the immunogenicity of induced pluripotent stem cells by the direct transplantation of undifferentiated cells into syngenic mice, indicating that cells differentiated from iPSCs can at least partially replace the biological functions of various organs.

Adult mice generated from induced pluripotent stem cells

Producing adult mice derived entirely from a reprogrammed fibroblast shows that all features of a differentiated cell can be restored to an embryonic level of pluripotency without exposure to unknown ooplasmic factors.

The Tumorigenicity of Mouse Embryonic Stem Cells and In Vitro Differentiated Neuronal Cells Is Controlled by the Recipients' Immune Response

Interestingly, the differentiated cells must contain a tumorigenic cell population that is not present among ES cells and which might be resistant to NK cell-mediated killing, and this clearly point to the importance of the immune response in this process.

Creation of Engineered Cardiac Tissue In Vitro From Mouse Embryonic Stem Cells

ES cells can be used as a source of seed cells for cardiac tissue engineering and both structurally and functionally resemble neonatal native cardiac muscle, according to Histological, immunohistochemical, and transmission electron microscopic studies.

iPS cells produce viable mice through tetraploid complementation

The generation of several iPS cell lines that are capable of generating viable, fertile live-born progeny by tetraploid complementation and confirm that iPS cells can attain true pluripotency that is similar to that of ES cells.

Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells

It is shown that iPSCs obtained from mouse fibroblasts, hematopoietic and myogenic cells exhibit distinct transcriptional and epigenetic patterns, and it is demonstrated that cellular origin influences the in vitro differentiation potentials of iPSC into embryoid bodies and different hematopsic cell types.

Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury

The directed neural differentiation of murine iPS cells is shown and it is suggested that pre-evaluated safe iPS clone-derived neural stem/progenitor cells may be a promising cell source for transplantation therapy for SCI.

Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors

The production of virus-free iPS cells, albeit from embryonic fibroblasts, addresses a critical safety concern for potential use of i PS cells in regenerative medicine.